The European Medicines Agency's CHMP has recommended approval of Novo Nordisk's Wegovy pill (oral semaglutide) for weight management in the EU. The pill showed a mean weight loss of 16.6% in trials, comparable to the injectable version, and also reduces major cardiovascular risks. It is the first oral GLP-1 treatment endorsed for obesity, with no drug interaction restrictions. Novo Nordisk plans to launch it outside the US in late 2026, aiming to meet rising demand for effective oral obesity treatments.
The European Medicines Agency's CHMP has recommended marketing authorization for Novo Nordisk's Wegovy 7.2 mg single-dose pen for obesity treatment in the EU. Clinical trials showed an average weight loss of 20.7% in obese patients, with about one-th...
Eli Lilly's experimental obesity drug retatrutide achieved a 28% body weight loss over 80 weeks in a pivotal phase III trial, surpassing Novo Nordisk's leading treatments Wegovy and Ozempic. While retatrutide shows higher efficacy, it also has a high...
Deutsche Bank maintains a 'hold' rating on Novo Nordisk with a price target of DKK290 after discussions with the company's head of R&D. Novo Nordisk is cautiously optimistic about its new obesity drug study, cagrisema RD11, which may outperform the p...
Novo Nordisk's stock has fallen about 70%, trading at roughly 10 times trailing earnings, presenting a buying opportunity. Despite setbacks in pricing and clinical trials, the company's promising drug pipeline, including high-dose Wegovy and other ca...
Eli Lilly's Mounjaro drug revenue surged 125% to $8.66 billion last quarter, prompting a raised full-year revenue forecast of $82-$85 billion and a market cap near $882 billion. Despite this, shares have already climbed significantly, making further ...
